ST. LOUIS, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS) and Westmead Hospital in Australia today announced findings of a recent study comparing the stability of a Niobe® remote magnetic navigation system catheter group and a manually controlled catheter group in a validated cardiac wall motion simulator.
"The Niobe system has long demonstrated an enhanced safety profile in comparison to conventional ablations, but its efficacy with lesion creation in highly mobile cardiac regions has not been adequately studied," said Pramesh Kovoor, M.D., Ph.D., Director of Cardiac Services at Westmead Hospital and Associate Professor at the University of Sydney. "We were pleasantly surprised with the results of our research, which provided strong evidence of faster, deeper lesion formation utilizing the Niobe system, due to constant catheter contact in the presence of simulated heart wall motion. As a practitioner, this translates into the potential for more precise, effective ablations in unstable regions of the heart, which could lead to improved patient outcomes and shorter procedure times."
During the study, the research team performed a total of 60 ablations in a myocardial phantom (gel tank), which was previously validated in animal studies. Radiofrequency ablations were delivered both by an irrigated catheter controlled by the Niobe magnetic navigation system as well as a manually controlled irrigated catheter, and catheter position was confirmed by real-time visualization. The ablation surface of the phantom was put into motion in order to simulate cardiac wall movement. Researchers observed lateral sliding (5.2mm) in the manual catheter group during surface movement, while the magnetically guided catheter group maintained stable focal contact with no lateral movement (0mm). As a result, lesion dimensions using the Niobe system were larger, deeper and formed sooner compared to manual control. Complete study results are available online in the Journal of Interventional Cardiac Electrophysiology (DOI: 10.1007/s10840-015-0023-3). Additional study details as well as a video of the study can be found at www.stereotaxis.com/lesion_westmead/.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis' systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the U.S., Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect", or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period, or at all, because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
CONTACT: STXS Company Contact: Martin Stammer Chief Financial Officer 314-678-6155 STXS Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 email@example.com